Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
WCLC 2016 – Lung Cancer
WCLC 2016 – Lung Cancer
Randomized, Phase 3 Study of First-Line Ceritinib vs Chemotherapy in Patients with ALK-Positive NSCLC (ASCEND-4)
WCLC 2016 – Lung Cancer
Conference Correspondent
Ceritinib is approved for use in patients with advanced
ALK
-positive non–small-cell lung cancer (NSCLC) who have progressed following treatment with crizotinib. In ASCEND-4, a multicenter randomized trial in previously untreated adult patients, researchers assessed progression-free survival outcomes for ceritinib compared with standard first-line and maintenance chemotherapy.
Read Article
Efficacy and Safety of Necitumumab plus Pembrolizumab in Patients Who Relapsed After Chemotherapy for Metastatic Nonsquamous NSCLC
WCLC 2016 – Lung Cancer
Conference Correspondent
Necitumumab, an epidermal growth factor receptor inhibitor, is approved with gemcitabine and cisplatin for previously untreated advanced squamous non–small-cell lung cancer (NSCLC). Nivolumab, a PD-1 inhibitor, is approved for previously untreated NSCLC, as well as relapsed NSCLC, based on PD-L1 expression. This phase 1b study evaluated combination use of these agents.
Read Article
Pembrolizumab + Carboplatin and Pemetrexed as First-Line Therapy for Advanced NSCLC (KEYNOTE-021 Cohort G)
WCLC 2016 – Lung Cancer
Conference Correspondent
Platinum-based chemotherapy with or without bevacizumab is standard first-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) without genetic aberrations. Pembrolizumab has demonstrated activity in PD-L1–positive advanced NSCLC. Cohort G of the phase 1/2 KEYNOTE-021 study compared pembrolizumab + carboplatin and pemetrexed (CP) with CP in patients with treatment-naive advanced nonsquamous NSCLC.
Read Article
Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation and PD-L1–Positive Metastatic NSCLC
WCLC 2016 – Lung Cancer
Conference Correspondent
Abemaciclib, a small-molecule inhibitor of both cyclin-dependent kinase (CDK)4 and CDK6, has demonstrated single-agent activity in patients with solid tumors, including non–small-cell lung cancer (NSCLC). Pembrolizumab, an inhibitor of PD-1, is approved for patients with metastatic PD-L1–positive NSCLC. Researchers studied abemaciclib combined with pembrolizumab in pretreated patients with NSCLC.
Read Article
Phase 3 Study of Alectinib vs Crizotinib in ALK-Positive NSCLC (J-ALEX)
WCLC 2016 – Lung Cancer
Conference Correspondent
Use of an ALK inhibitor is standard in patients with
ALK
-positive non–small-cell lung cancer (NSCLC). In this phase 3 study, researchers compared 2 ALK inhibitors: crizotinib and alectinib. This randomized trial was designed to demonstrate superior progression-free survival for alectinib compared with crizotinib in ALK-inhibitor–naïve
ALK
-positive NSCLC.
Read Article
Efficacy and Safety of Necitumumab Continuation After Triplet Therapy in Patients with EGFR-Expressing NSCLC (SQUIRE)
WCLC 2016 – Lung Cancer
Conference Correspondent
The SQUIRE study demonstrated that the addition of necitumumab to gemcitabine plus cisplatin improved overall survival in patients with metastatic squamous non–small-cell lung cancer (NSCLC). Researchers evaluated the clinical outcomes associated with this triplet regimen in a subset of patients in the SQUIRE trial whose tumors expressed an epidermal growth factor receptor (EGFR).
Read Article
First-Line Afatinib versus Gefitinib in EGFR-Mutated Advanced NSCLC: Updated Overall Survival (OS) Analysis of LUX-Lung 7
WCLC 2016 – Lung Cancer
Conference Correspondent
Afatinib, an irreversible ErbB family blocker, and gefitinib, a reversible EGFR tyrosine kinase inhibitor, are approved for first-line treatment of advanced
EGFR
-mutated non–small-cell lung cancer (NSCLC). Researchers reported updated OS findings from a phase 2b trial (LUX-Lung 7) that compared afatinib versus gefitinib in first-line patients.
Read Article
Subgroup Analyses from Randomized Phase 3 Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC (OAK)
WCLC 2016 – Lung Cancer
Conference Correspondent
Atezolizumab, a humanized anti–PD-L1 monoclonal antibody, is approved for the treatment of patients with metastatic non–small-cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. OAK is one of the 2 international, randomized, open-label clinical trials that demonstrated superior efficacy for atezolizumab over docetaxel.
Read Article
Nivolumab vs Nivolumab with Ipilimumab in Recurrent Small-Cell Lung Cancer (SCLC) (CheckMate 032)
WCLC 2016 – Lung Cancer
Conference Correspondent
Patients with SCLC whose disease progressed during or after initial platinum-based chemotherapy have few treatment options. Nivolumab alone and combined with ipilimumab has demonstrated clinical benefit in multiple tumor types. Researchers presented updated results for the SCLC cohort of the phase 1/2 CheckMate 032 trial.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma